Bioequivalence of Genotropin and Somatonorm
- 1 July 1987
- journal article
- Published by Wiley in Acta Paediatrica
- Vol. 76 (s337) , 118-121
- https://doi.org/10.1111/j.1651-2227.1987.tb17141.x
Abstract
The bioequivalence parameters, AUC, Cmax and Tmax were calculated from serum hGH concentration-time curves after subcutaneous injections of Genotropin (recombinant somatropin) and Somatonorm (somatrem) in a two-period crossover study in 11 healthy men aged 21-35 years. Cmax was 53.4 and 62.9 mIU/litre and Tmax was 5.3 and 4.0 hours for Genotropin and Somatonorm, respectively. Criteria for bioequivalence were fulfilled for AUC. The bioavailability of Genotropin given subcutaneously was determined from the data obtained in the study above, and after an intravenous injection of Genotropin in the same dose (0.1 IU/kg body weight). The measured bioavailability of 71% could be an overestimate due to interference by endogenous hGH.Keywords
This publication has 5 references indexed in Scilit:
- GROWTH HORMONE PRETREATMENT IN MAN BLOCKS THE RESPONSE TO GROWTH HORMONE‐RELEASING HORMONE; EVIDENCE FOR A DIRECT EFFECT OF GROWTH HORMONEClinical Endocrinology, 1987
- An exact confidence interval from untransformed data for the ratio of two formulation meansJournal of Pharmacokinetics and Biopharmaceutics, 1984
- Short-term study of biosynthesized hGH in man.Endocrinologia Japonica, 1983
- BIOSYNTHETIC METHIONYL HUMAN GROWTH HORMONE IS BIOLOGICALLY ACTIVE IN ADULT MANThe Lancet, 1982